Rhabdomyolysis after BNT162b2 mRNA Covid-19  vaccine in an adolescent male

Sütçü, Murat; Gül, Doruk; Atik, Fatih; Kara, Manolya

doi:10.4314/mmj.v34i2.13

Cited by 4 publications

(3 citation statements)

References 11 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, 10 cases of rhabdomyolysis after COVID-19 vaccination have been reported. In these cases, the patients were vaccinated with Moderna, Comirnaty, AstraZeneca, Johnson & Johnson, and a non-specified COVID-19 vaccine [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rhabdomyolysis after COVID-19 Comirnaty Vaccination: A Case Report

Ruijters¹,

Meulen²,

Es³

et al. 2022

Case Rep Neurol

View full text Add to dashboard Cite

Rhabdomyolysis is an acute disruption in skeletal muscle integrity, leading to the rapid release of 4 muscle contents into the bloodstream, such as creatine kinase (CK). It can have various causes, including infections. Throughout the pandemic, multiple cases of rhabdomyolysis following COVID-19 infections have been reported. However, rhabdomyolysis subsequent to COVID-19 vaccinations appears to be relatively rare. Here, we report such a case after a second COVID-19 Comirnaty (BioNTech/Pfizer) vaccination. Our patient developed rhabdomyolysis 1 day after the second Comirnaty vaccination with high creatine kinase (CK) levels, generalized weakness, and kidney failure. CK levels and muscle weakness resolved after treatment with intravenous fluids, but unfortunately, he remained hemodialysis dependent after discharge. To our knowledge, this is one of the first case reports describing a patient with rhabdomyolysis after a Comirnaty vaccination. However, as millions of people have received the Comirnaty vaccine, it is unclear whether the rhabdomyolysis in our patient is a rare side effect or an unrelated, coincidental event. Large observational studies are needed to elucidate the causality between the Comirnaty vaccination and rhabdomyolysis. Awareness is warranted in patients with myalgia and muscle weakness shortly after COVID-19 vaccination, in order to initiate treatment early and prevent life-threatening complications.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In 4/10 cases, complaints and CK levels resolved partly after discharge but with limited follow-up [ 4 , 5 , 6 , 11 ]. In 4/10 cases, complaints and CK levels resolved completely [ 7 , 8 , 9 , 12 ]. In one case, the rhabdomyolysis was fatal [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Rhabdomyolysis after COVID-19 Comirnaty Vaccination: A Case Report

Ruijters¹,

Meulen²,

Es³

et al. 2022

Case Rep Neurol

View full text Add to dashboard Cite

show abstract

“…One case, Gelbenegger et al, was not due to mRNA vaccination, and, in fact, we discussed and cited rhabdomyolysis events after a viral vector COVID-19 vaccination in our paper [ 2 ]. The other two pediatric cases were Sutcu et al which was published July 1, 2022, and Kim et al which was published in 2023 [ 3 , 4 ]. Further, as we stated in our article, we queried the vaccine adverse event reporting system (VAERS) on June 22, 2022.…”

mentioning

confidence: 99%